This enzyme is a key target for anticancer drugs like methotrexate (MTX), which competitively inhibits human DHFR, leading to reduced thymidylate levels and impaired DNA synthesis in rapidly dividing cancer cells [5,6,7,8]. Here, DHFR is linked to cancer.